All In Biotech

Investigational drug · Phase 3

Verducatib

Also called: BI 1291583

Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Bronchiectasis, Chronic Obstructive Pulmonary Disease.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

4

4 still active

All registered trials

20

Any phase or sponsor naming "Verducatib"

First trial start

2023

Sep 8, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Verducatib", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Bronchiectasis
  • Chronic Obstructive Pulmonary Disease

Approved drugs for the same conditions: COPD · Respiratory

Largest trials

Live from ClinicalTrials.gov: studies naming "Verducatib" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 12 on PubMed

Also in development for Bronchiectasis

  • ItepekimabREGN3500, SAR440340Phase 39 trials

    Sanofi · Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps, Bronchiectasis

  • HSK31858Phase 33 trials

    Haisco Pharmaceutical Group Co., Ltd. · Non-cystic Fibrosis Bronchiectasis, Asthma Bronchiale, Bronchiectasis

  • CHF10196florensocatibPhase 31 trial

    Chiesi Farmaceutici S.p.A. · Bronchiectasis

  • GSK3862995BPhase 22 trials

    GSK · Bronchiectasis, Pulmonary Disease, Chronic Obstructive

  • CHF6333Phase 21 trial

    Chiesi Farmaceutici S.p.A. · Bronchiectasis

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Boehringer Ingelheim.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.